Daniel G Miller

List of Publications by Year
in descending order

44 papers	6,739 citations	147801 31 h-index	254184 43 g-index
45 all docs	45 docs citations	45 times ranked	5594 citing authors

#	Article	IF	Citations
1	Gene Therapy for Facioscapulohumeral Muscular Dystrophy (FSHD). , 2019, , 509-524.		1
2	GGC Repeat Expansion and Exon 1 Methylation of XYLT1 Is a Common Pathogenic Variant in Baratela-Scott Syndrome. American Journal of Human Genetics, 2019, 104, 35-44.	6.2	81
3	MRI change metrics of facioscapulohumeral muscular dystrophy: Stir and T1. Muscle and Nerve, 2018, 57, 905-912.	2.2	29
4	Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures. Human Molecular Genetics, 2018, 27, 2644-2657.	2.9	6
5	Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele. Epigenetics and Chromatin, 2018, 11, 47.	3.9	26
6	Underperforming Big Ideas in Biomedical Research. JAMA - Journal of the American Medical Association, 2017, 317, 321.	7.4	2
7	Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures. Skeletal Muscle, 2017, 7, 13.	4.2	17
8	Epigenetic memory via concordant DNA methylation is inversely correlated to developmental potential of mammalian cells. PLoS Genetics, 2017, 13, e1007060.	3.5	17
9	A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD). Neuromuscular Disorders, 2016, 26, 405-413.	0.6	36
10	A Human Pluripotent Stem Cell Model of Facioscapulohumeral Muscular Dystrophy-Affected Skeletal Muscles. Stem Cells Translational Medicine, 2016, 5, 1145-1161.	3.3	98
11	Clinical trial preparedness in facioscapulohumeral muscular dystrophy: Clinical, tissue, and imaging outcome measures 29â€“30 May 2015, Rochester, New York. Neuromuscular Disorders, 2016, 26, 181-186.	0.6	43
12	VISA - Vector Integration Site Analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing. BMC Bioinformatics, 2015, 16, 212.	2.6	37
13	Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. Human Molecular Genetics, 2015, 24, 5901-5914.	2.9	159
14	Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Human Molecular Genetics, 2015, 24, 659-669.	2.9	130
15	Longitudinal features of stir bright signal in FSHD¹. Muscle and Nerve, 2014, 49, 257-260.	2.2	46
16	Wnt/Î²-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells. Human Molecular Genetics, 2013, 22, 4661-4672.	2.9	92
17	Chromatin structure of two genomic sites for targeted transgene integration in induced pluripotent stem cells and hematopoietic stem cells. Gene Therapy, 2013, 20, 201-214.	4.5	39
18	Epigenetic regulation of the X-chromosomal macrosatellite repeat encoding for the cancer/testis gene CT47. European Journal of Human Genetics, 2012, 20, 185-191.	2.8	15

#	Article	IF	Citations
19	Facioscapulohumeral muscular dystrophy. Current Opinion in Neurology, 2012, 25, 614-620.	3.6	42
20	Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature Genetics, 2012, 44, 1370-1374.	21.4	582
21	AAV-Mediated Gene Targeting. Methods in Molecular Biology, 2012, 807, 301-315.	0.9	9
22	Asymmetric Bidirectional Transcription from the FSHD-Causing D4Z4 Array Modulates DUX4 Production. PLoS ONE, 2012, 7, e35532.	2.5	20
23	A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy. Science, 2010, 329, 1650-1653.	12.6	638
24	Frequent Endonuclease Cleavage at Off-target Locations In Vivo. Molecular Therapy, 2010, 18, 983-986.	8.2	54
25	Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed Gene. PLoS Genetics, 2010, 6, e1001181.	3.5	394
26	Efficient KRT14 Targeting and Functional Characterization of Transplanted Human Keratinocytes for the Treatment of Epidermolysis Bullosa Simplex. Molecular Therapy, 2010, 18, 1624-1632.	8.2	43
27	Characterization of microRNAs Involved in Embryonic Stem Cell States. Stem Cells and Development, 2010, 19, 935-950.	2.1	156
28	RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Human Molecular Genetics, 2009, 18, 2414-2430.	2.9	182
29	Comparison of HIV-derived Lentiviral and MLV-based Gammaretroviral Vector Integration Sites in Primate Repopulating Cells. Molecular Therapy, 2007, 15, 1356-1365.	8.2	104
30	AAV Vector Integration Sites in Mouse Hepatocellular Carcinoma. Science, 2007, 317, 477-477.	12.6	532
31	Unique Integration Profiles in a Canine Model of Long-Term Repopulating Cells Transduced with Gammaretrovirus, Lentivirus, or Foamy Virus. Human Gene Therapy, 2007, 18, 423-434.	2.7	73
32	Gene targeting in vivo by adeno-associated virus vectors. Nature Biotechnology, 2006, 24, 1022-1026.	17.5	102
33	Foamy virus vector integration sites in normal human cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1498-1503.	7.1	226
34	Integration Bias of Gammaretrovirus Vectors following Transduction and Growth of Primary Mouse Hematopoietic Progenitor Cells with and without Selection. Molecular Therapy, 2006, 14, 226-235.	8.2	14
35	Large-Scale Analysis of Adeno-Associated Virus Vector Integration Sites in Normal Human Cells. Journal of Virology, 2005, 79, 11434-11442.	3.4	148
36	EfficientPRNPGene Targeting in Bovine Fibroblasts by Adeno-Associated Virus Vectors. Cloning and Stem Cells, 2004, 6, 31-36.	2.6	16

#	Article	IF	Citations
37	Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Medicine, 2004, 10, 828-834.	30.7	586
38	Adeno-associated virus vectors integrate at chromosome breakage sites. Nature Genetics, 2004, 36, 767-773.	21.4	226
39	Human Gene Targeting by Adeno-Associated Virus Vectors Is Enhanced by DNA Double-Strand Breaks. Molecular and Cellular Biology, 2003, 23, 3550-3557.	2.3	123
40	Chromosomal effects of adeno-associated virus vector integration. Nature Genetics, 2002, 30, 147-148.	21.4	148
41	Gene Therapy for Hemophilia. New England Journal of Medicine, 2001, 344, 1782-1784.	27.0	22
42	Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 78-82.	7.1	407
43	Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7071-7075.	7.1	623
44	[40] Use of retroviral vectors for gene transfer and expression. Methods in Enzymology, 1993, 217, 581-599.	1.0	395